Does Cyp3a Inducers Interact with Pralsetinib?
Cyp3a Inducers and Pralsetinib have a major drug interaction according to U.S. FDA drug labeling data. Concomitant use decreases pralsetinib exposure, which may decrease efficacy of GAVRETO. Avoid coadministration; if unavoidable, increase GAVRETO dose. The mechanism involves cyp3a induction decreases pralsetinib exposure. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Major
- Pralsetinib Class
- Kinase Inhibitor
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
How This Interaction Works
The interaction between Cyp3a Inducers and Pralsetinib occurs because cyp3a induction decreases pralsetinib exposure. Clinically, this means concomitant use decreases pralsetinib exposure, which may decrease efficacy of gavreto. avoid coadministration; if unavoidable, increase gavreto dose. This is classified as a major interaction, meaning it could cause serious harm if not properly managed. Your healthcare provider may need to adjust dosages, substitute one medication, or increase monitoring frequency.
What To Tell Your Doctor or Pharmacist
If you are taking Cyp3a Inducers and your doctor is considering prescribing Pralsetinib (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider